Skip to main content
Articles & Publications , Dr. Andrew Lewis , Artificial Intelligence

How AI-Guided Drug Formulation Can Accelerate Clinical Development

Quotient Sciences Chief Scientific Officer Dr. Andrew Lewis discusses how machine learning can guide formulation optimization using emerging clinical data, helping sponsors identify promising formulations sooner while reducing development time, API use and unnecessary formulation iterations

Connecting Formulation, Manufacturing and Clinical Data to Make Faster Decisions  

Quotient Sciences’ integrated approach brings formulation development, drug product manufacturing and clinical testing together within a single development model. This can reduce the traditional hand-offs between different providers while allowing formulation scientists to respond rapidly to emerging clinical data.

Read the full article on biopharmaboardroom.com website.

Latest news from Quotient Sciences

More News
Articles & Publications, Dr. Andrew Lewis, Artificial Intelligence How AI-Guided Drug Formulation Can Accelerate Clinical Development By: Andy Lewis
Read More
Articles & Publications, John McDermott, Dr. Andrew Lewis, Artificial Intelligence How AI Is Transforming Formulation Development Through Predictive Design By: John McDermott and Andy Lewis
Read More
News & Announcements, Nottingham, UK, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline By: Dr. Andrew Lewis
Read More
Let's Talk
Your breakthrough therapy deserves momentum, and every day matters. Start a conversation with us today.